A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia
Sponsor: Merck Sharp & Dohme LLC
A PHASE2 clinical study on Alzheimer Disease and Dementia, this trial is actively recruiting participants. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 15 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 10 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
First recorded
Dec 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .